Company Filing History:
1 out of 30 
1 out of 1 Years Active: 2010-2016
Title: Innovations in Neuroprotection: The Contributions of Annina Roeytenberg
Introduction
Annina Roeytenberg is a prominent inventor based in San Francisco, CA, who has made significant strides in the field of neuroprotection and treatment for neurodegenerative diseases. With a focus on innovative pharmaceutical compositions, she has developed methods that aim to improve the quality of life for patients suffering from conditions such as Alzheimer's disease.
Latest Patents
Roeytenberg holds two notable patents that address critical issues in neurodegeneration. Her first patent involves pharmaceutical compositions for the treatment of patients with neurodegeneration following ischemic insult. This invention includes a method of administering deferoxamine (DFO) to the upper one-third of the nasal cavity, allowing it to bypass the blood-brain barrier and directly target the central nervous system. The second patent focuses on methods and pharmaceutical compositions for preconditioning the central nervous system against neurological disorders, including Alzheimer's disease, Parkinson's disease, and other related conditions. This method aims to stimulate and stabilize hypoxia-inducible factor-1α (HIF-1α), providing neuroprotective benefits under ischemic conditions.
Career Highlights
Throughout her career, Annina Roeytenberg has worked with reputable organizations such as HealthPartners Research Foundation. Her research has contributed to the understanding and treatment of neurodegenerative diseases, showcasing her commitment to advancing medical science.
Collaborations
Roeytenberg has collaborated with notable professionals in her field, including William Howard Frey II and Samuel Scott Panter. These collaborations have further enriched her research and innovations in neuroprotection.
Conclusion
Annina Roeytenberg's contributions to the field of neuroprotection through her innovative patents and collaborations highlight her dedication to improving patient outcomes in neurodegenerative diseases. Her work continues to pave the way for future advancements in medical treatments.